Trial Profile
A phase III randomized double-blind pivotal trial of immunotherapy with a polyvalent melanoma vaccine, CancerVax vaccine [cancer vaccine] plus BCG versus placebo plus BCG as a post-surgical treatment for stage IV melanoma
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 14 Aug 2018
Price :
$35
*
At a glance
- Drugs Cancer vaccine (Primary) ; BCG
- Indications Malignant melanoma
- Focus Registrational; Therapeutic Use
- Sponsors CancerVax Corporation
- 03 Nov 2005 New trial record.